drug
dabigatran etexilate mesylate
Marketedupdated 3mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
indications
investigational
Atrial Fibrillation
all catalysts(0)
nothing on the calendar yet
Trials studying dabigatran etexilate mesylate
- N/ACan the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF
- phase1A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
- —Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 20, 2031
~4.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Jul 20, 2031patentUS 9034822*PED5.0y
- Jul 20, 2031patentUS 9034822*PED5.0y
- Jul 20, 2031patentUS 9034822*PED5.0y
- Jan 20, 2031method-of-use (U-1759)US 90348224.5y
- Jan 20, 2031method-of-use (U-1759)US 90348224.5y
- Jan 20, 2031method-of-use (U-1759)US 90348224.5y
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Mar 7, 2026patentUS 7932273*PED
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
- Sep 7, 2025compositionUS 7932273
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that